SCHEMBL4650946

SCHEMBL4650946

CCN(C(=O)CC(NS(=O)(=O)c1ccccc1)c1ccc(OCC(=O)O)c(C(=O)O)c1)c1c[nH]c2cc(OC)ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
GRK2 P25098 1/20 0.44
DUSP3 P51452 1/20 0.44
PTPN5 P54829 1/20 0.44
PTPN11 Q06124 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MMP2 P08253 6/20 0.38
MMP9 P14780 6/20 0.38
KMT2A Q03164 2/20 0.37
FPR1 P21462 1/20 0.37
HAT1 O14929 2/20 0.36
EP300 Q09472 2/20 0.36
MAPT P10636 2/20 0.36
MMP13 P45452 1/20 0.35
MMP14 P50281 1/20 0.35
ADAM17 P78536 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
KCNA5 P22460 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4650899 0.94 POLB (0.47) POLBGRK2DUSP3PTPN5PTPN11
SCHEMBL7050666 0.85 POLB (0.40) POLBGRK2DUSP3PTPN5PTPN11
SCHEMBL4651292 0.79 ATM (0.38) POLBGRK2DUSP3PTPN5PTPN11
SCHEMBL4651316 0.75 ALDH1A1 (0.48) POLBMMP2MMP9KMT2AALDH1A1
SCHEMBL4650872 0.73 ALDH1A1 (0.60) POLBKMT2AALDH1A1GAASMN1; SMN2
SCHEMBL7050019 0.72 ALDH1A1 (0.54) POLBKMT2AALDH1A1MEN1
SCHEMBL4650942 0.71 PTPN1 (0.50) MMP2MMP9KMT2AMAPTMMP13
SCHEMBL4650884 0.70 PTPN1 (0.49) MMP2MMP9MMP14ALDH1A1
SCHEMBL4651379 0.70 ALDH1A1 (0.58) POLBKMT2AMAPTALDH1A1GAA
SCHEMBL7053662 0.69 ALDH1A1 (0.47) POLBMMP2MMP9KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1301474-A2 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS Array Biopharma Inc. (US) 2003-04-16 EP claimed
US-20020040003-A1 Preparation of phosphatase inhibitors ARRAY BIOPHARMA INC. 2002-04-04 US claimed
WO-2002004412-A2 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2002-01-17 WO claimed
EP-1301474-B1 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC (US) 2008-09-10 EP disclosed
US-6586467-B2 Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus ARRAY BIOPHARMA INC. 2003-07-01 US disclosed
US-20020040003-A1 Preparation of phosphatase inhibitors ARRAY BIOPHARMA INC. 2002-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040003-A1 Preparation of phosphatase inhibitors PTPRS, PTPRO, PTPRR POLB 3603/4885GRK2 1143/4885DUSP3 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.